Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

[1]  C. Rizzi.  Statistical Methods , 2020, Springer Theses.

[2]  A. Stamatoullas,et al.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). , 2010, Leukemia research.

[3]  G. Zanninelli,et al.  Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients , 2009, British journal of haematology.

[4]  A. Taher,et al.  Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study , 2009, European journal of haematology.

[5]  A. Taher,et al.  Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia , 2009, European journal of haematology.

[6]  M. Cappellini,et al.  High nontransferrin bound iron levels and heart disease in thalassemia major , 2009, American journal of hematology.

[7]  P. Greenberg,et al.  International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes , 2008, American journal of hematology.

[8]  Emanuele Angelucci,et al.  Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias , 2008, Haematologica.

[9]  Dominica H. C. Wong,et al.  Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy , 2008 .

[10]  M. Cazzola,et al.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.

[11]  Y. Eshet,et al.  No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique , 2007, American journal of hematology.

[12]  John C Wood,et al.  Magnetic resonance imaging measurement of iron overload , 2007, Current opinion in hematology.

[13]  M. Tallman,et al.  The Myelodysplastic Syndromes: Help Is On The Way! , 2007 .

[14]  A. Cnaan,et al.  Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. , 2006, Blood.

[15]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Pouchard,et al.  Redox active plasma iron in C282Y/C282Y hemochromatosis. , 2005, Blood.

[17]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[18]  M. Pouchard,et al.  Redox active plasma iron in C 282 Y / C 282 Y hemochromatosis , 2005 .

[19]  D. Pennell,et al.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.

[20]  Marvin D Nelson,et al.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.

[21]  Z. Cabantchik,et al.  Labile plasma iron in iron overload: redox activity and susceptibility to chelation. , 2003, Blood.

[22]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[23]  E. Neufeld,et al.  Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial , 2003, The Lancet.

[24]  D. Bowen,et al.  Oxidative Stress and the Myelodysplastic Syndromes , 2003, International journal of hematology.

[25]  T. S. St. Pierre,et al.  Proton transverse relaxation rate (R2) images of iron‐loaded liver tissuepping local tissue iron concentrations with MRI , 2003 .

[26]  A. Tordai,et al.  High Incidence of Hemochromatosis Gene Mutations in the Myelodysplastic Syndrome: The Budapest Study on 50 Patients , 2003, Acta Haematologica.

[27]  T. S. St. Pierre,et al.  Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI [corrected]. , 2003, Magnetic resonance in medicine.

[28]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[29]  L. Grummer-Strawn,et al.  Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. , 2001, JAMA.

[30]  M. Kami,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[31]  A. Hoffbrand,et al.  Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.

[32]  C. McLaren,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[33]  T. S. St. Pierre,et al.  Quantitative mapping of transverse relaxivity (1/T(2)) in hepatic iron overload: a single spin-echo imaging methodology. , 2000, Magnetic resonance imaging.

[34]  M. Cappellini,et al.  Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? , 2000, The hematology journal : the official journal of the European Haematology Association.

[35]  G. Link,et al.  Pathophysiology of Iron Overload a , 1998, Annals of the New York Academy of Sciences.

[36]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[37]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[38]  R. Hoffman,et al.  Hematology: Basic Principles and Practice , 1995 .

[39]  M. Cazzola,et al.  Natural history of idiopathic refractory sideroblastic anemia , 1988 .

[40]  D. Galton.  The myelodysplastic syndromes. , 1987, Clinical and laboratory haematology.